Influenza viruses cause substantial morbidity and mortality through seasonal epidemics and occasional pandemics. Vaccination has been an effective approach in prevention of infection with seasonal influenza but not pandemic viruses. The constant antigenic drift of circulating viruses, as well as the vast diversity of zoonotic viruses that might enter the human population, pose persistent threats to human health. In the event of a pandemic outbreak, vaccine production against the emerging virus would lag several months behind the emergence of the new virus. Thus, prevention or treatment strategies that can cover a broad range of viral strains and subtypes are urgently needed. Currently, antiviral strategies in development include universal influenza vaccines 1 , broadly neutralizing therapeutic antibodies 2 and small-molecule inhibitors 3 .
a r t i c l e s
Influenza viruses cause substantial morbidity and mortality through seasonal epidemics and occasional pandemics. Vaccination has been an effective approach in prevention of infection with seasonal influenza but not pandemic viruses. The constant antigenic drift of circulating viruses, as well as the vast diversity of zoonotic viruses that might enter the human population, pose persistent threats to human health. In the event of a pandemic outbreak, vaccine production against the emerging virus would lag several months behind the emergence of the new virus. Thus, prevention or treatment strategies that can cover a broad range of viral strains and subtypes are urgently needed. Currently, antiviral strategies in development include universal influenza vaccines 1 , broadly neutralizing therapeutic antibodies 2 and small-molecule inhibitors 3 .
HA is the major surface envelope protein of influenza A and B viruses. It carries essential functions in the viral life cycle. Viral entry is mediated by attachment through HA binding to sialic acid receptors on the host membrane and then internalization of viral particles into the late endosome 4 . The HA receptor-binding site is a shallow depression in the globular head at the extreme membrane-distal end of HA and is surrounded by structural elements commonly referred to as the 220 loop, 130 loop, 150 loop and 190 helix, named after their sequence numbers in the mature HA protomer 4 . Although HAs of different subtypes from different hosts display some unique structural features around the receptor-binding pocket, which determine their fine specificity and avidity, a large portion of the receptor-binding site is highly conserved for the recognition of the common ligand, the terminal sialic acid of sialylated glycans. Most notably, a hydrophobic cavity at the 150 loop end of the receptor-binding site, which accommodates the 5-acetamido moiety of sialic acid, is formed by the universally conserved HA residues Trp153, Leu194 and Tyr195 and other conserved residues from the 130 and 150 loops.
The exposed receptor-binding-site pocket has been of interest for inhibitor design since the identification of sialic acid as the viral receptor 5 and the structural determination of HA in complex with sialic acid 6 in the 1980s. However, design of sialic acid analogs as inhibitors has failed to yield high-affinity binders to the shallow receptor-binding site with broad specificity against human-infecting HA subtypes 7 , probably because sialic acid itself is a low-affinity binder (low mM) 8 . Derivatives of N-acetylneuraminic acid (Neu5Ac) often improve their affinity only through acquiring additional interactions with nonconserved HA residues near the receptor-binding site. Recent approaches have used polyvalent presentation of sialic acid analogs to enhance their inhibitory activity by mimicking the multivalent binding between virus and host cell 7 . However, these applications have raised concern of toxicity and drug delivery 7 . Research in the last three decades suggests that Neu5Ac presents an insurmountable challenge for drug design at the receptor-binding pocket, and a new chemical scaffold that can access novel ligand-HA interactions is urgently needed.
The receptor-binding site of HA also presents a potential target for engagement with antibodies. Because the receptor-binding site must be exposed for binding to host glycan receptors, this site cannot be blocked by the dense glycan shield that is used by some viruses to mask themselves from surveillance by the host immune system 9,10 . However, most previously known epitopes map to the most accessible hypervariable regions, which surround the receptor-binding site and are not well conserved among different influenza subtypes and strains 11 . Antibodies to these hypervariable loops select for escape a r t i c l e s mutants and lead to antigenic drift on a population level. In recent months, antibody identification efforts, coupled in some cases with structural studies, have revealed that the receptor-binding site of HA itself also can serve as a main site for antibody-antigen interactions. The human antibodies CH65 and C05 and the mouse antibody S139/1 each insert a complementarity-determining region (CDR) loop into the receptor-binding site [12] [13] [14] . Several antibodies encoded by the human VH1-69 gene segment (official symbol IGHV1-69) also were proposed to recognize epitopes at or near the receptor-binding pocket of HA 15, 16 . Unlike most anti-HA head antibodies, these antibodies to the receptor-binding site demonstrated a notable ability to broadly neutralize a large number of strains from a single HA subtype or selected strains from different subtypes and groups of influenza viruses. CH65 neutralizes a wide spectrum of seasonal H1 viruses isolated in the past 30 years 12 . S139/1 was the first head-specific antibody to be described to neutralize strains from different subtypes (H1, H2, H3 and H13) and from the two phylogenetic lineages (group 1 and 2) of influenza A viruses 17 . C05 has similar breadth and binds and/or neutralizes selected strains from H1, H2, H3, H9 and H12 subtypes 13 . The human VH1-69-encoded antibody F045-092 also has been reported to cross-neutralize strains from multiple subtypes (H1, H2, H3, H5) 15 . Thus, these antibodies do not simply block the receptor-binding site but also must have a footprint that avoids interaction with many of the hypervariable residues surrounding the receptor-binding site, at least within subtypes or across selected strains from different subtypes.
We recently described the first naturally occurring human monoclonal antibodies specific for the globular head of H2N2 influenza HA, designated 8F8, 8M2 and 2G1, that were generated with hybridoma technology from the peripheral blood of middle-aged donors 16 . These three antibodies showed a similar spectrum, reacting with human H2N2 viruses that circulated between 1957 to 1963 as well as with a swine H2N3 strain isolated in 2006 (ref. 16 ). Antibody 2G1 also showed hemagglutination-inhibition (HAI) activity against a tested H3 strain (A/Hong Kong/1/1968) 16 . H2N2 was the sole influenza A virus in human circulation between 1957 and 1968, causing several epidemics 18, 19 and an excess mortality of up to 66,000 deaths in the US alone during the 1957-1958 pandemic season 20 . It is estimated that up to 4 million people worldwide died owing to influenza A infections over this 12-year period 21 . H2N2 has not recurred in humans, but strains similar to the 1957 pandemic strain continue to circulate in avian [22] [23] [24] and swine 23 reservoirs. As human herd immunity to H2N2 wanes, these H2 viruses have increasing potential to reenter the human population from these animal reservoirs 21 .
Here, we set out to study the structural basis of neutralization by these human anti-H2 antibodies. The fragment antigen-binding regions (Fabs) of the three H2-neutralizing antibodies were crystallized and their structures determined in complex with H2 HA to elucidate their mode of binding and mechanism of neutralization. These three antibodies, in conjunction with the reports of other headbinding antibodies 12, 13 , have helped us to uncover new mechanisms of neutralization and have provided chemical scaffolds that may aid in the design of drugs against the receptor-binding-site pocket.
RESULTS

Antibodies 2G1 and 8M2
Germline VH1-69 is the only human heavy-chain gene segment that encodes two hydrophobic residues at the tip of the CDR2 loop: namely Ile53 and Phe54 (ref. 25) . Antibodies derived from this germline gene segment are known to bind conserved hydrophobic pockets on the envelope proteins of hepatitis C virus [26] [27] [28] , human immunodeficiency virus 25, 29, 30 and the stem region of influenza A viruses [31] [32] [33] . Germline gene VH1-69-encoded stem-region antibodies of influenza HA target a conserved hydrophobic patch on the HA stem that is not fully protected by glycosylation. In the last few months, some VH1-69-encoded antibodies have been described that appear to recognize epitopes near the HA receptor-binding site, but the exact structural nature of such antibody recognitions has not been elucidated 15, 16 . Here, we determined the crystal structures of H2 HA (A/Japan/305+/1957) in complex with the Fab fragments of two VH1-69-encoded antibodies, 2G1 and 8M2, to provide the first structural illustration, to our knowledge, of how VH1-69 antibodies bind the HA receptor-binding site.
Fab fragments of 2G1 and 8M2 were expressed in mammalian cell line 293F suspension culture. Purified Fab and the recombinant H2 HA ectodomain were mixed and passed through a gel-filtration column to isolate stable HA-Fab complexes for crystallization. Crystal structures of 8M2-H2 HA and 2G1-H2 HA complexes were determined at 3.1-and 3.2-Å resolution, respectively ( Table 1) .
Antibodies 2G1 and 8M2 approach the HA receptor-binding site from a similar direction but a completely opposite orientation (Fig. 1a,b) . Three Fabs bind per trimer. The heavy-chain CDR (HCDR) loops of both antibodies are centered on the HA receptorbinding site, engaging residues in and around the region where sialic acid binds (Fig. 2) . The 2G1 light chain contacts HA residues near the 150 loop that would correspond to the Sa antigenic site in H1 HA (Fig. 2a) . In contrast, the 8M2 light chain contacts the HA around the N-terminal end of the 190 helix, with these interactions being mediated only by light-chain CDR 3 (LCDR3) (Fig. 2b,d ). The heavy chain of both antibodies mediates the majority of the antigenantibody contacts, contributing to 73% of the buried interface on 34 .
A common feature of 2G1 and 8M2 heavy-chain binding is the insertion of Phe54, one of the signature residues on HCDR2 of VH1-69-encoded germline antibodies ( Supplementary Fig. 1 ), into a hydrophobic pocket in the receptor-binding site. In both structures, the aromatic side chain of Phe54 enters a cavity in the receptorbinding site and is buried by conserved hydrophobic residues on the HA (Fig. 3a,b) . The phenylalanine aromatic rings are nearly perpendicular to the indole side chain of HA Trp153 and make optimal π-π interactions. Ile53, the other hallmark hydrophobic residue from the VH1-69 germline sequence at the tip of HCDR2, is also present in both 2G1 and 8M2. As a result of differences in the relative antibody orientations, Ile53 contacts different hydrophobic patches in the HA receptor-binding site in the two structures. Ile53 interacts with the 190 helix in the 2G1 complex, whereas it forms van der Waals contacts with the 130 loop in the 8M2 complex (Fig. 3a,b) . Furthermore, this Ile53 and Phe54 hydrophobic pair provides 199 Å 2 and 207 Å 2 to the HA-antibody interface in 2G1 and 8M2, respectively.
The antibody-antigen interactions are otherwise different in the 8M2 and 2G1 complexes, owing to the difference in antibody orientation. The heavy chain of 8M2 sits atop the receptor-binding site and completely blocks the entry of glycan receptors. HCDR2 and HCDR3 extend into the receptor-binding site and make extensive contacts to HA residues lining this site (Fig. 3b) . The HCDR2 loop is positioned on the 150-loop side of the receptor-binding site. Aside from the hydrophobic contacts mediated by Ile53 and Phe54, the Ser56-Pro57-Asn58 segment of HCDR2 interacts with the HA 150 loop through van der Waals contacts and hydrogen bonds, with the Ser56 hydroxyl group hydrogen bonding to Gly158 and Ser159 main chain nitrogens. Ser56 and Pro57 arose from somatic mutations (Supplementary Fig. 1 ) and were probably acquired during affinity maturation of antibody 8M2. The HDCR3 loop, in contrast, reaches into the receptor-binding-site pocket from the 220 loop side (Fig. 3b) . Glu98 of 8M2 hydrogen bonds with the main chain nitrogen of HA1 Arg137. The carbonyl oxygen of Gly100 hydrogen-bonds with the backbone amides of Gly227 and Ser228. The Trp99 indole of 8M2 lies atop the 190 helix of HA. The tip of HCDR3 main chain (Gly100 and Ser100A; antibody residues are listed in the Kabat numbering scheme, with insertions denoted by sequential letters) makes extensive contact with the Leu226 side chain. As a result, 8M2 does not recognize avian-like H2 HAs on blue native PAGE (BN-PAGE), which have Gln226 instead of the human receptorspecific Leu226 (data not shown). Antibody 8M2 also does not have HAI or neutralization activity against avian-like H2 viruses 16 .
In the 2G1 complex, a ridge on the HA surface formed by part of the 150 loop (residues 157-159) serves as the boundary between the binding footprints of the 2G1 heavy and light chains (Fig. 2a) . The heavy chain targets the receptor-binding site, and the light chain recognizes part of the β-sheet that roughly corresponds to the Sa antigenic site in the H1 subtype. HCDR2 and HCDR3 insert into (Fig. 3a) . The HCDR2 loop extends toward the conserved HA1 Trp153 from about the middle section of the receptor-binding site. Ile53 and Phe54 at the tip of the HCDR2 are buried inside the receptor-binding pocket. The HCDR2 loop twists at Gly55 and brings Gly55 and Thr56 close to the 130 loop. These HCDR2 residues are conserved from the germline sequence (Supplementary Fig. 1 ) and contribute to HA binding. HCDR3 also inserts into the binding pocket, but not as deeply as HCDR2, and covers the upper half of the 150 loop (residues 156-159). Overall, the heavy chain of 2G1 uses 593 Å 2 of antibody surface area to bury 543 Å 2 of HA at the antibody-HA interface. The interactions mediated by the heavy chain are mostly van der Waals contacts with few polar interactions. The only hydrogen bond is between 2G1 Ser99 and HA1 Thr131 side chains. By comparison, 225 Å 2 of the 2G1 light-chain surface covers 235 Å 2 of HA at the antibody-HA interface.
Thus, the structural analysis of these two antibodies reveals surprising similarities and diversities and illustrates a common theme for antibody recognition of the most conserved part of the HA receptor-binding site.
8F8-H2 HA complex
The signature π-π interaction between HCDR2 Phe54 and HA Trp153, as employed by the two VH1-69 germline antibodies, is notably mirrored by a third anti-H2 human antibody, 8F8, encoded by a different germline gene segment (VH3-33; official symbol IGHV3-33). Using similar methods as for 8M2 and 2G1, we determined the crystal structure of Fab 8F8 in complex with H2 HA (an L226Q S228G mutant of A/Japan/305+/1957) at 3-Å resolution ( Fig. 4a and Table 1 ). The 8F8 heavy chain is encoded by VH3-33 and its light chain by VL1-44 (official symbol IGLV1-44) (Fig. 4b) . Three 8F8 Fabs bind per HA trimer, and they approach the receptor-binding site from a similar direction to those of 8M2 and 2G1, that is, vertically from the top with respect to the apex of the head domain. The antibodyantigen interface is dominated by the 8F8 heavy chain (Fig. 5a,b) , which accounts for 92% of the buried surface area on the Fab (775 out of 847 Å 2 ) and 91% of the buried interface on the HA (748 out of 827 Å 2 ). The antibody binding footprint includes absolutely conserved residues at the bottom of the receptor-binding-site pocket (Tyr98 and Trp153) that interact with sialic acid and also includes residues from the surrounding structural elements: the 130 loop (residues 131-145 contact antibody), the 150 loop (155-159), the 190 helix (187-196) and the 220 loop (225-226) (Fig. 5a ). An avianized H2 HA, which has the avian-like substitutions L226Q and S228G on the 220 loop for binding α2,3-linked sialylated glycans, was used for the crystallization with 8F8. The substitutions do not appear to affect antibody binding, as 8F8 comigrates with wild-type as well as avianized H2 HA on BN-PAGE (data not shown). The 220 loop contributes only modest surface area (26 Å 2 ) to 8F8 recognition. 
npg a r t i c l e s
On the antibody side, the centerpiece for antibody-antigen interactions is the HCDR3 loop that is relatively long, at 21 amino acids (Figs. 4b and 5b) . HCDR3 loop residues provide nearly 70% of the interface area from the antibody (583 out of 847 Å 2 ) and form a wide bulge with a short helix that nestles into the receptor-binding site. Near the top of the bulge, the Tyr100 aromatic side chain inserts into the hydrophobic pocket surrounded by HA1 Gly134-Gly135, Trp153, Thr155 and Leu194-Tyr195, forming yet another π-π stacking interaction with the conserved HA Trp153. In addition to these extensive hydrophobic interactions, a hydrogen bond is formed between the Tyr100 hydroxyl and the HA1 Thr155 side chain (Fig. 5c) . Around Tyr100, the HCDR3 loop snakes through the HA receptor-binding pocket, making extensive hydrophobic contacts as well as some hydrophilic interactions with the 130 loop and 150 loop (Fig. 5c) . Most notably, Asp97 forms a salt bridge with HA1 Arg137. Ser100A mediates two main chain hydrogen bonds with HA1 Gly135. On the 150 loop end, HCDR3 Asp100D and Tyr100G hydrogen-bond with HA1 Thr155, Glu156 and Gly158. After traversing the receptor-binding site, HCDR3 turns around and adopts a helical structure that makes extensive contacts with the 190 helix that are mostly hydrophobic. On the antibody side, the helix-helix contacts are dominated by three aromatic residues, Tyr100G, His100J and Tyr100K, which together provide 190 Å 2 buried interface on 8F8 (Fig. 5c) .
Previously, antibody CH65 was shown to have its HCDR3 inserted into the receptor-binding site of H1 HA 12 . Some similarities are apparent between CH65 and 8F8 binding, with both HCDR3 loops inserting into the elongated HA receptor-binding pocket (Fig. 5d) . However, the HCDR3 loops from these two antibodies approach the receptor-binding site from opposite directions and use different sets of antibody-antigen interactions. An aspartic acid (Asp100C) on CH65 appears to mimic the sialic acid carboxylate interactions with HA, but a similar contact is absent in the 8F8 complex. Instead, 8F8 HCDR3 inserts more deeply into the receptor-binding pocket and makes more extensive contacts with conserved residues inside the pocket. 8F8 Tyr100 replaces CH65 Val100B as the residue inserting into the HA hydrophobic cavity above Trp153. A π-π interaction between the antibody and HA Trp153 is absent in the CH65 complex but is replaced by a hydrophobic interaction. Similarly, in antibody S139/1 the pocket is occupied by HCDR2 Met56 (ref. 14) . In antibody C05, a tryptophan residue from HCDR3 occupies this hydrophobic pocket in the HA 17 .
Escape mutants and receptor binding
The three anti-H2 antibodies recognize epitopes extensively covering the receptor-binding site of HA. HA escape mutations from the three anti-H2 antibodies may be located close to the receptorbinding site and thus interfere with receptor binding, an essential viral function of HA, and impair viral fitness. Escape mutants were selected in chicken eggs in the presence of the anti-H2 antibodies 16 . An escape mutation, G135D, was selected for antibody 8M2 and a K156E mutation for 2G1. For 8F8, a T193K mutation can escape antibody binding. Another 8F8-escape mutation, R137Q, greatly reduces the HAI activity of 8F8 toward H2N2 virus-like particles (VLPs) 16 . These escape mutations are located within the binding footprint of their respective antibodies (Fig. 6a) . However, these residue locations on the rim of the receptor-binding pocket might also affect receptor binding. Therefore, we introduced these single mutations on the background of A/Japan/305+/1957 H2 HA and studied their glycanbinding activities on a glycan microarray (Fig. 6b,c and Supplementary  Fig. 2) . The wild-type HA shows strong binding to a broad spectrum of α2,6-linked glycans as well as to glycans with mixed α2,3 and α2,6 linkages (Fig. 6b) . Binding specificity for α2,6-but not α2,3-linked sialylated glycans is a general property shared by HAs of human viruses. The tested mutations drastically changed the receptorbinding activity of HA. Only the R137Q mutant retained some weak binding for one biantennary glycan (glycan #55; Fig. 6c ), which has Fig. 2 ), which suggests greatly diminished or abolished binding for sialic acid receptors in the escape mutants.
In the 12-year circulation of H2N2 viruses in the human population, mutations of G135D, R137Q and K156E were found sporadically in human H2 viruses, but viruses with these mutations did not become established 16 . Instead, later strains (1962-1968) accumulated mutations either at the same positions but with only very subtle changes to the amino acid properties or at locations further from the receptor-binding site 16 .
DISCUSSION
H2N2 viruses circulated in the human population for 12 years after their introduction during the Asian flu pandemic in 1957. The circulation period of H2N2 viruses was relatively short compared to that of the H1N1 and H3N2 viruses, which have lasted for several decades. It was hypothesized that antibody binding to highly conserved epitopes on the H2 HA may have limited its ability to evolve under human immune selection 35 . One such conserved epitope is the stem region of H2 HA, as identified by escape mutations 36 .
The receptor-binding site of H2 HA is another highly conserved epitope where antigenic drift could potentially interfere with viral fitness. Three anti-H2 antibodies generated from the peripheral blood of healthy donors all target the receptor-binding pocket and probably block entry of glycan receptor. With the limited number of antibodies studied here, it is difficult to speculate what percentage of anti-H2 antibodies in infected or vaccinated individuals targets the receptor-binding site. However, in a study of mouse antibodies, half of the anti-H2 HA antibodies were sensitive to residue changes that are associated with the avian-to-human HA receptor-specificity switch 37 , which suggests that many mouse antibodies also target the receptor-binding site of H2 HA and engage HA residues critical for receptor binding.
Antibody recognition of the receptor-binding site presents a challenge for the antigenic drift of viruses, a necessary counteraction against human immune surveillance. Mutations that inhibit antibody binding have to strike a delicate balance to inhibit or greatly reduce antibody binding without completely abrogating HA receptor binding. Escape mutants of antibodies 8F8, 8M2 and 2G1 isolated in vitro introduce amino acid changes into the centers of the antibody footprints. Although these mutations are effective in abolishing antibody binding, they also reduce HA binding activity and, without compensating mutations, are probably detrimental to the survival of the mutant viruses. In field strains, these same mutations were spotted occasionally but not inherited by later strains, which suggests that they are dead-end mutations. If antibodies such as 2G1, 8M2 or 8F8 were present at the population level, they probably would limit the circulation of H2 viruses in the human population.
Influenza antibodies encoded by the VH1-69 germline gene segment were conventionally thought of as being stem-specific antibodies. Here, we show that their germline characteristics are also ideally suited for recognition of another structurally conserved influenza functional epitope, the HA receptor-binding pocket. Two VH1-69-encoded antibodies studied here, 2G1 and 8M2, were cloned from two different donors yet use shared conserved elements of the HCDR2 germline sequence and structure for antigen recognition. These shared structural features are further evidence of antibody convergence 38 toward similar modes of interaction with the receptorbinding site.
Structural analysis of the three antibody complexes presented here along with the recently described C05, CH65 and S139/1 antibody npg a r t i c l e s complexes reveals the HA receptor-binding site as a conserved epitope and reveals a potentially druggable pocket inside the HA receptorbinding site. A notably common theme arises from these three crystal structures. Tyr100 from HCDR3 of antibody 8F8 and Phe54 from HCDR2 of antibodies 2G1 and 8M2 insert their aromatic side chains into a hydrophobic cavity at the 150-loop end of the receptor-binding site (Fig. 7a) . Furthermore, CH65 inserts a hydrophobic side chain (Val100B) from HCDR3 into the same cavity 16 , C05 positions another aromatic side chain from HCDR3 proximal to Trp153 (ref. 13) , and S139/1 uses another hydrophobic residue, HCDR2 Met56 (ref. 14) . During glycan-receptor binding, this hydrophobic cavity is occupied by the methyl group from the 5-acetamide of sialic acid (Fig. 7b) , which suggests that structural conservation here is probably essential for virus receptor binding. In the H2-antibody complexes, the aromatic rings are situated for optimal π-π interaction with HA Trp153 and are surrounded by HA residues Gly134-Gly135, Thr155, Leu194 and Tyr195, all of which are highly conserved in influenza A viruses. Thus, only through structure determination of these H2-antibody complexes could this recurrent theme be noticed. It is therefore plausible that inhibitors, either small proteins or small-molecule compounds, could be designed to target this conserved hydrophobic cavity and mimic the antibody interactions. The presentations of these aromatic residues into the HA hydrophobic cavity provide valuable starting points and new scaffolds for inhibitor designs. Drug design toward the highly conserved cavity thus has the potential to inhibit all influenza A and possibly influenza B HA subtypes.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes.
Coordinates and structure factors have been deposited in the Protein Data Bank, with accession codes 4HF5, 4HFU and 4HG4.
